Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Research & Development of $29.5 million for Q2 2026, up 33.23% year-over-year from $22.1 million in Q2 2025, and up 5.88% on a QoQ basis from $27.8 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Research & Development for 16 years, with the latest figure at $29.5 million in Q2 2026.
- Research & Development for Q2 2026 came in at $29.5 million, up 33.23% year-over-year; the trailing twelve-month figure through Jun 2026 was $108.8 million (up 1.92% YoY), and the FY2025 annual result was $106.2 million, down 2.35% from the prior year.
- Research & Development grew to $29.5 million in Q2 2026, from $27.8 million in the prior quarter.
- Over five years, Research & Development peaked at $29.5 million in Q2 2026 and troughed at $16.4 million in Q2 2022.
- A 5-year average of $24.2 million and a median of $24.4 million in 2023 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development fell 15.68%; it then jumped 48.79% in 2023.
- A 5-year view of Research & Development shows it stood at $17.8 million in 2022, then surged by 31.35% to $23.3 million in 2023, then advanced by 22.7% to $28.6 million in 2024, then slipped by 2.86% to $27.8 million in 2025, then rose by 5.88% to $29.5 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $29.5 million in Q2 2026, $27.8 million in Q4 2025, and $29.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn | 29.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.46 Mn |
| Dec 31, 2025 | 27.83 Mn |
| Sep 30, 2025 | 29.37 Mn |
| Jun 30, 2025 | 22.12 Mn |
| Mar 31, 2025 | 26.93 Mn |
| Dec 31, 2024 | 28.65 Mn |
| Sep 30, 2024 | 29.04 Mn |
| Jun 30, 2024 | 26.18 Mn |
| Mar 31, 2024 | 24.93 Mn |
| Dec 31, 2023 | 23.35 Mn |
| Sep 30, 2023 | 22.66 Mn |
| Jun 30, 2023 | 24.38 Mn |
| Mar 31, 2023 | 21.21 Mn |
| Dec 31, 2022 | 17.77 Mn |
| Sep 30, 2022 | 19.55 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 20.84 Mn |
| Dec 31, 2021 | 21.08 Mn |
| Sep 30, 2021 | 19.65 Mn |
| Jun 30, 2021 | 15.46 Mn |